SecBot SecBot
Biotech Drug Report Generated Nov 3, 2026

ACAM2000

EBS·Emergent BioSolutions Inc.
NEUTRAL
Drug Impact Rating4/10
Trial phase
Approved
Time to market
Already approved and marketed since 2007 (smallpox) and 2024 (mpox).
Why 4/10
ACAM2000 is already FDA-approved and commercially marketed with no pending PDUFA date, AdComm, or pivotal readout in the next 12 months; the next catalysts are U.S. government contract option exercises and international regulatory decisions, which are not hard binary events, so the impact score is capped at 4 per the rubric.
Actionable Insight NEUTRAL

ACAM2000 is an approved, revenue-generating product with no pending FDA binary catalyst. Watch for U.S. government contract option exercises (the 10-year ASPR deal has annual renewals) and further international approvals, which drive lumpy quarterly revenue. The Q3 2026 revenue miss and lowered guidance are the near-term headwind to watch.

Price Chart

Loading chart...

Executive Summary

ACAM2000 is an FDA-approved live vaccinia virus vaccine for smallpox (since 2007) and mpox (expanded approval August 2024), manufactured by Emergent BioSolutions (NYSE: EBS). It is one of only two FDA-approved vaccines covering both diseases and is primarily sold to the U.S. government for the Strategic National Stockpile under a 10-year contract. In 2025, total projected ACAM2000 sales exceeded $120 million. However, the drug faces competition from Bavarian Nordic's JYNNEOS, a safer non-replicating vaccine preferred for routine mpox use. ACAM2000 revenue is lumpy and tied to government delivery timing: Q3 2026 Smallpox MCM revenues fell 68% year-over-year, contributing to a weak quarter that sent the stock down sharply. The drug is approved and commercialized with no pending FDA binary catalyst, making it a steady but unpredictable revenue contributor within Emergent's broader biodefense portfolio.

How It Works

ACAM2000 is a live vaccine made from vaccinia virus, a close relative of the smallpox and mpox viruses. It is administered by scratching the skin with a special two-pronged needle (scarification), which triggers the immune system to produce protective antibodies. Because it uses a live, replicating virus, it generates strong immunity but carries a higher risk of side effects than non-replicating vaccines.

Trial Status

ACAM2000 was FDA-approved in August 2007 for smallpox prophylaxis and received supplemental approval in August 2024 for mpox prevention. It is manufactured and supplied to the U.S. Strategic National Stockpile under a long-term government contract. International approvals were obtained in Singapore and Saudi Arabia in 2026.

The Two-Sided Case

▲ Bull Case5
ACAM2000 is one of only two FDA-approved vaccines for both smallpox and mpox, with a long track record since 2007 and a place in the U.S. Strategic National Stockpile.
The U.S. government has a 10-year contract with annual option renewals: a $56M modification in September 2025 and a $52.7M modification in June 2026, with total projected 2025 ACAM2000 sales exceeding $120 million.
International expansion is underway: Saudi Arabia approved ACAM2000 in May 2026 and Singapore approved an expanded mpox indication, opening new non-U.S. revenue streams.
Analyst consensus is bullish: 5 Buy/Strong Buy ratings vs 1 Hold and 1 Sell, with a mean price target of $11 (61.5% implied upside from the $6.81 close on Nov 2, 2026).
Major institutional investors added or doubled positions in Q2 2026, including Millennium Management (doubled to $9M), Goldman Sachs (added to $8.7M), and Prudential (added to $6.8M).
▼ Bear Case5
ACAM2000 faces competition from JYNNEOS (Bavarian Nordic), a safer non-replicating vaccine that the CDC prefers for mpox outbreaks and that has largely replaced ACAM2000 in clinical use.
ACAM2000 is a live replicating vaccinia virus vaccine with a known safety risk of myocarditis and other serious adverse reactions, limiting its addressable population.
Revenue is highly dependent on lumpy U.S. government contract timing: Q3 2026 Smallpox MCM product revenues (which include ACAM2000) fell 68% year-over-year due to delivery timing, contributing to a 52% total revenue decline and a net loss.
Emergent lowered full-year 2026 revenue and adjusted EBITDA guidance after Q3 results, and the stock fell sharply in post-market trading on November 2, 2026.
Insider sales occurred in October 2026: a director sold $126K worth of shares and an SVP sold $19.6K, both under 10b5-1 plans.

Upcoming Catalysts

  • U.S. government contract option year renewals under the 10-year ASPR agreement (annual exercises, next due in 2027)
  • Potential additional international regulatory approvals for smallpox and mpox indications
  • Quarterly revenue reports reflecting ACAM2000 delivery timing to the U.S. government

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Emergent BioSolutions Inc. 8-K EBS ·Originating report

Sources · 10

Hover a chip for the title
1 fda.gov2 en.wikipedia.org3 drugs.com4 investors.emergentbiosolutions.com5 investors.emergentbiosolutions.com6 sec.gov7 investors.emergentbiosolutions.com8 tradingkey.com9 cdc.gov10 pmc.ncbi.nlm.nih.gov